Status:
COMPLETED
A Survey About Trade-offs When Choosing Menopause Treatments
Lead Sponsor:
Astellas Pharma Europe Ltd.
Conditions:
Moderate to Severe Vasomotor Symptoms
Eligibility:
FEMALE
40-65 years
Brief Summary
This study is an online survey of women in menopause with moderate to severe hot flashes. Menopause, a normal part of life, is the time after a woman's last period. Hot flashes often occur during meno...
Eligibility Criteria
Inclusion
- Resident of Australia, Canada, Denmark, France, Germany, Italy, Spain, Sweden, or the United Kingdom
- Experience at least 14 moderate or severe VMS episodes associated with menopause per week (or 2 to 3 episodes per day)
- Self-reported completion of natural menopause (post-menopausal)
- Willing and able to provide consent to take part in the study; Speak native language of country of participation
- Telephone interview only: Willing and able to participate in a telephone interview, and be audio recorded
Exclusion
- Experienced treatment related menopause either as a result of medical or surgical intervention
- Difficulty understanding or communicating in the language(s) of Australia, Canada, Denmark, France, Italy, Spain, Sweden, or the United Kingdom
- Online survey only: Participation in the Telephone interview
Key Trial Info
Start Date :
August 17 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 27 2023
Estimated Enrollment :
1465 Patients enrolled
Trial Details
Trial ID
NCT05300568
Start Date
August 17 2022
End Date
August 27 2023
Last Update
October 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site GB44001
Hammersmith, United Kingdom